Medicare for All Could Stifle Drug Innovation, CBO Says

Drug Industry Daily
Prescription drug costs would likely have a small impact on federal spending under a single-payer system but a national health system might have the unintended consequence of forcing drugmakers to stop taking risks on new medicines, the Congressional Budget Office says in a new analysis released Wednesday.

To View This Article:


Subscribe To Drug Industry Daily